Evofem Biosciences Files 8-K: Material Agreement & Equity Sales
Ticker: EVFM · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1618835
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: EVFM
TL;DR
EVFM filed an 8-K for a material agreement and equity sales. Details TBD.
AI Summary
Evofem Biosciences, Inc. announced on October 28, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement, sales, and financial performance were not provided in this initial filing.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate actions like a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- October 28, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36754 (identifier) — Commission File Number
- 20-8527075 (identifier) — I.R.S. Employer Identification No.
- 7770 Regents Road , Suite 113-618 San Diego , California 92122 (address) — Principal executive offices
- (858) 550-1900 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the Material Definitive Agreement entered into by Evofem Biosciences?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on or before October 28, 2024.
What type of equity securities were sold in the unregistered sales?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 28, 2024.
What is Evofem Biosciences' principal executive office address?
Evofem Biosciences' principal executive office is located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
What are the key items disclosed in this 8-K filing?
This 8-K filing discloses an entry into a Material Definitive Agreement, unregistered sales of equity securities, and financial statements and exhibits.
Filing Stats: 1,038 words · 4 min read · ~3 pages · Grade level 12.2 · Accepted 2024-10-28 08:15:24
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $2,280,000 — ck") for an aggregate purchase price of $2,280,000. The powers, preferences, rights, quali
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex10-1.htm (EX-10.1) — 294KB
- ex10-2.htm (EX-10.2) — 222KB
- 0001493152-24-042605.txt ( ) — 842KB
- evfm-20241028.xsd (EX-101.SCH) — 3KB
- evfm-20241028_lab.xml (EX-101.LAB) — 33KB
- evfm-20241028_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: October 28, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer